SCHEMBL6035855

SCHEMBL6035855

CCOC(=O)CCc1cn(-c2ccccn2)nc1OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.49
CYP4A11 Q02928 2/20 0.49
LMNA P02545 3/20 0.44
ALDH1A1 P00352 5/20 0.41
MAPT P10636 1/20 0.40
HPGD P15428 2/20 0.40
ATM Q13315 1/20 0.40
DGAT1 O75907 1/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
RAB9A P51151 1/20 0.40
SLC11A2 P49281 1/20 0.39
CREBBP Q92793 1/20 0.39
KDM4E B2RXH2 2/20 0.38
HSD17B10 Q99714 2/20 0.38
GAA P10253 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5385710 0.82 DGAT1 (0.36) CYP4F2CYP4A11LMNAALDH1A1MAPT
SCHEMBL7543721 0.82 DGAT1 (0.36) CYP4F2CYP4A11LMNADGAT1
SCHEMBL6035929 0.81 DGAT1 (0.38) ALDH1A1MAPTHPGDATMDGAT1
SCHEMBL6034456 0.81 L3MBTL1 (0.42) CYP4F2CYP4A11LMNAALDH1A1MAPT
SCHEMBL7543726 0.79 CYP4F2 (0.34) CYP4F2CYP4A11LMNAALDH1A1ATM
SCHEMBL5403139 0.76 CYP4F2 (0.48) CYP4F2CYP4A11LMNAALDH1A1MAPT
SCHEMBL6035915 0.76 PPARG (0.40) CYP4F2CYP4A11ALDH1A1DGAT1CYP2C9
SCHEMBL5373814 0.76 CYP4F2 (0.50) CYP4F2CYP4A11LMNAALDH1A1CREBBP
SCHEMBL6035551 0.76 CYP4F2 (0.41) CYP4F2CYP4A11LMNAALDH1A1DGAT1
SCHEMBL6251865 0.75 LMNA (0.39) LMNAALDH1A1MAPTDGAT1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 CYP4F2 90/4885CYP4A11 18/4885LMNA 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.